Prescient reports dose optimisation review outcome for Phase 2a PTX-100 CTCL study

Key Highlights:

- The Dose Optimisation Committee (DOC) has completed its first review of data from the ongoing Phase 2a study of PTX-100 in relapsed or refractory cutaneous T-cell lymphoma (CTCL)
- PTX-100 was well tolerated with no major safety concerns and modest efficacy in the first 20 participants evaluable for efficacy (10 per dose arm), 2 study participants achieved a complete response, 12 had stable disease and 6 had disease progression
- The DOC considered the available data insufficient to select a dose and recommended that enrolment in the study continue
- The Company will undertake a review of the PTX-100 program in light of the clinical data and the DOC's recommendation

MELBOURNE Australia, 25th November 2026 – Prescient Therapeutics (ASX: PTX), a clinical-stage oncology company developing targeted cancer therapies, announces the outcome of the first Dose Optimisation Committee (DOC) meeting of its Phase 2a study of PTX-100 in patients with relapsed or refractory CTCL. PTX-100 is a first-in-class compound with the ability to block an enzyme, GGTase-1, that can contribute to cancer growth.

The DOC met on the 24th November 2026 to review the available safety, pharmacokinetic and efficacy data from the ongoing PTX-100-02-2024 study in patients with relapsed or refractory CTCL. The study is a two-part Phase 2a trial, with up to 40 evaluable participants to be enrolled in the first part, evaluating two doses (500 and 1000 mg/m2) of PTX-100.

"PTX-100 continues to be well tolerated. Two patients have achieved a complete response, which is a meaningful outcome for patients with relapsed or refractory CTCL, with 60% of patients having stable disease. However, overall efficacy at this stage has been modest, and the DOC considered the data insufficient to select a dose. The Company will undertake a review of the PTX-100 program to determine the best path forward for patients and shareholders," said James McDonnell, CEO of Prescient Therapeutics.

Study data*

At the data cut-off, 29 patients were evaluable for safety, having received at least one dose of PTX-100; and 20 patients were evaluable for efficacy, having had at least one Global Response Score (GRS) assessment after 4 cycles. Treatment with PTX-100 was well tolerated with no adverse events leading to drug discontinuation and no serious adverse events related to PTX-100. The study's pre-defined safety stopping rules were not met. Of the 20 patients evaluable for efficacy, there were 2 patients with a complete response, 12 with stable disease and 6 with disease progression. The two patients with complete response and 5 patients with stable disease remain on treatment.

DOC recommendation and next steps

The DOC recommended that enrolment in the study continue. The Company will undertake a review of the PTX-100 program, which will consider the DOC's recommendation and the study data. Enrolment in the study will continue while the review is undertaken.

PTX-100 holds FDA Orphan Drug Designation for T-cell lymphomas and EMA orphan designation for CTCL. It also holds FDA Fast Track Designation for adults with relapsed or refractory mycosis fungoides (April 2025).

To stay updated with the latest company news and announcements, please update your details in our investor centre.

*These results are preliminary. They include data that are not yet fully source-verified, and may differ at later analyses. Comparisons with other trials are subject to differences in trial design, response criteria and patient populations.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries

James McDonnell
CEO
Prescient Therapeutics
james.mcdonnell@ptxtherapeutics.com

Investor & Media enquiries

Haley Chartres
H^CK HQ
04 2313 9163
haley@hackhq.com.au

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical-stage oncology company developing personalised cancer treatments through targeted therapies and advanced cell therapy enhancement platforms.

Targeted Therapy

PTX-100 is a first-in-class compound with the ability to block an enzyme that can contribute to cancer growth known as geranylgeranyl transferase-1 (GGTase-1). Blocking this target disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral signaling circuits in cancer cells, leading to their apoptosis (death). Mutations in Ras pathways are believed to be involved in up to 22% of all cancers.

PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and in a recent PK/PD basket study of hematological and solid malignancies. PTX-100 has completed a Phase 1b expansion cohort study in T-cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T-Cell Lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. The Phase 2 study in r/r Cutaneous T-cell lymphoma (CTCL) has completed its first Dose Optimisation Committee review of 20 evaluable patients (10 in each dosing arm), and the Company is reviewing next steps for the program.

Cell Therapy Platforms

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in preclinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of

CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pretreated CAR-T cells.

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

Find out more at www.ptxtherapeutics.com or connect with us via LinkedIn.

Forward Looking Statements

This announcement contains forward-looking statements based on current expectations, estimates, and assumptions. These statements are subject to risks and uncertainties that may cause actual results to differ materially. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this announcement. Prescient undertakes no obligation to revise forward-looking statements except as required by law.